Ginkgo Bioworks Holdings Inc. (DNA)
NYSE NYSE Primary 
XMEX 
23andMe goes bankrupt, will now auction off DNA data
23andMe has proposed a May 14 auction for the sale of its assets, which include the genetic data of more than 15 million customers. The sale of genetic data raises concerns about privacy and safety, and customers are worried about what this means for their personal information.
23andMe has filed for bankruptcy. What does this mean for your DNA data privacy?
The genetic testing company 23andMe has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what will happen to their genetic data.
DNA testing pioneer 23andMe files for bankruptcy as concerns mount over data privacy of 15M customers
DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company's more than 15 million customers.
DNA testing firm 23andMe files for bankruptcy protection
DNA testing firm 23andMe has filed for bankruptcy protection in the US, marking the collapse of one of the most high-profile names in consumer genetics. Co-founder Anne Wojcicki has stepped down as chief executive with immediate effect, though she will remain on the board.
DNA testing firm 23andMe files for Chapter 11 bankruptcy to sell itself
Genetic testing firm 23andMe filed for Chapter 11 bankruptcy in the U.S. on Sunday and said it was looking to sell itself.
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
VW's cheapest EV will have Rivian DNA and who is bidding for Canoo's assets
Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!
Resilience is part of our DNA, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering profitable growth in 2025.
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
